Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2004

01-09-2004 | Original Paper

Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target

Authors: Su-Hyeong Kim, Sang-Hyun Song, Sang-Gyun Kim, Kyung-Soo Chun, So-Young Lim, Hye-Kyung Na, Jae Weon Kim, Young-Joon Surh, Yung-Jue Bang, Yong-Sang Song

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2004

Login to get access

Abstract

Purpose

Recently, many studies have shown that celecoxib induces apoptosis in various cancer cells by different mechanisms depending on the cell type. This study examined the apoptotic effect of celecoxib in cervical cancer cells and its mechanism.

Methods

Cell viability was measured by MTT assay and apoptosis was examined by DNA fragmentation and flow cytometry. Western blotting and immunoprecipitation were used to explore various mechanisms of celecoxib-induced apoptosis. The activation of NF-κB was confirmed by EMSA.

Results

Celecoxib induced apoptosis independent of COX-2 activity. This event accompanied the activation of caspase-8 and -9 with Bid cleavage and the loss of mitochondrial membrane potential. The protective effect of caspase-8 and -9 inhibitors on celecoxib-induced apoptosis suggests the importance of caspase-8 and -9 activation in this apoptotic pathway. Fas/FADD-mediated apoptotic pathway was detected only in C33A cells, demonstrated by the immunoprecipitation of Fas-FADD in celecoxib-treated cells and the protective effect of FADD dominant negative mutant. Finally, NF-κB appeared to be involved in celecoxib-induced apoptosis, as revealed by increased NF-kB DNA binding activity in a time-dependent manner and attenuation of its proapoptotic effect by N-tosyl-L-phenylalanyl-chloromethyl ketone, an NF-kB blocker.

Conclusions

These data show that caspase-8 and -9 are involved in the apoptotic effect of celecoxib in cervical cancer cells. This requires the FADD-dependent pathway in a cell type-specific manner. In addition, NF-κB may play a key role in celecoxib-induced apoptosis.
Literature
go back to reference Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:838–847PubMed Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:838–847PubMed
go back to reference Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA, Schwarz T (1998) Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 140:171–182CrossRefPubMed Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA, Schwarz T (1998) Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 140:171–182CrossRefPubMed
go back to reference Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7:1410–1418PubMed Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7:1410–1418PubMed
go back to reference Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D (1995) A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 270:7795–7798CrossRefPubMed Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D (1995) A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 270:7795–7798CrossRefPubMed
go back to reference Castano E, Dalmau M, Barragan M, Pueyo G, Bartrons R, Gil J (1999) Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. Br J Cancer 81:294–299 Castano E, Dalmau M, Barragan M, Pueyo G, Bartrons R, Gil J (1999) Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. Br J Cancer 81:294–299
go back to reference Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225–242PubMed Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225–242PubMed
go back to reference Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160:893–903PubMed Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160:893–903PubMed
go back to reference Dubois RN (2000) Review article: cyclooxygenase—a target for colon cancer prevention. Aliment Pharmacol Ther 14[Suppl 1]:64–67 Dubois RN (2000) Review article: cyclooxygenase—a target for colon cancer prevention. Aliment Pharmacol Ther 14[Suppl 1]:64–67
go back to reference Elder DJ, Paraskeva C (1998) COX-2 inhibitors for colorectal cancer. Nat Med 4:392–393PubMed Elder DJ, Paraskeva C (1998) COX-2 inhibitors for colorectal cancer. Nat Med 4:392–393PubMed
go back to reference Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO (2002a) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20:973–981CrossRefPubMed Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO (2002a) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20:973–981CrossRefPubMed
go back to reference Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G (2002b) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85:305–310CrossRefPubMed Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G (2002b) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85:305–310CrossRefPubMed
go back to reference Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M (2001) Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49:1213–1217CrossRefPubMed Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M (2001) Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49:1213–1217CrossRefPubMed
go back to reference Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R, Olsson CA (1999) Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53:440–445CrossRefPubMed Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R, Olsson CA (1999) Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53:440–445CrossRefPubMed
go back to reference Grossman EM, Longo WE, Panesar N, Mazuski JE, Kaminski DL (2000) The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis 21:1403–1409CrossRefPubMed Grossman EM, Longo WE, Panesar N, Mazuski JE, Kaminski DL (2000) The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis 21:1403–1409CrossRefPubMed
go back to reference Han SS, Keum YS, Seo HJ, Chun KS, Lee SS, Surh YJ (2001a) Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Lett 164:119–126PubMed Han SS, Keum YS, Seo HJ, Chun KS, Lee SS, Surh YJ (2001a) Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Lett 164:119–126PubMed
go back to reference Han Z, Pantazis P, Wyche JH, Kouttab N, Kidd VJ, Hendrickson EA (2001b) A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J Biol Chem 276:38748–38754CrossRefPubMed Han Z, Pantazis P, Wyche JH, Kouttab N, Kidd VJ, Hendrickson EA (2001b) A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J Biol Chem 276:38748–38754CrossRefPubMed
go back to reference Higashi Y, Kanekura T, Kanzaki T (2000) Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 86:667–671CrossRefPubMed Higashi Y, Kanekura T, Kanzaki T (2000) Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 86:667–671CrossRefPubMed
go back to reference Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000a) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397–11403PubMed Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000a) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397–11403PubMed
go back to reference Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000b) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397–11403PubMed Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000b) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397–11403PubMed
go back to reference Husain SS, Szabo IL, Tamawski AS (2002) NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 97:542–553CrossRef Husain SS, Szabo IL, Tamawski AS (2002) NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 97:542–553CrossRef
go back to reference Ishiko O, Sumi T, Yoshida H, Matsumoto Y, Honda K, Deguchi M, Yamada R, Ogita S (2001) Association between overexpression of cyclooxygenase-2 and suppression of apoptosis in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion. Oncol Rep 8:1259–1263PubMed Ishiko O, Sumi T, Yoshida H, Matsumoto Y, Honda K, Deguchi M, Yamada R, Ogita S (2001) Association between overexpression of cyclooxygenase-2 and suppression of apoptosis in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion. Oncol Rep 8:1259–1263PubMed
go back to reference Jendrossek V, Handrick R, Belka C (2003) Celecoxib activates a novel mitochondrial apoptosis signaling pathway. Faseb J 17:1547–1549 PubMed Jendrossek V, Handrick R, Belka C (2003) Celecoxib activates a novel mitochondrial apoptosis signaling pathway. Faseb J 17:1547–1549 PubMed
go back to reference Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, Slosberg ED, Soh JW, Weinstein IB, Wong BC (2002) Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 21:6113–6122CrossRefPubMed Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, Slosberg ED, Soh JW, Weinstein IB, Wong BC (2002) Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 21:6113–6122CrossRefPubMed
go back to reference Johnson AJ, Song X, Hsu A, Chen C (2001) Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41:221–235CrossRefPubMed Johnson AJ, Song X, Hsu A, Chen C (2001) Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41:221–235CrossRefPubMed
go back to reference Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861–867PubMed Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861–867PubMed
go back to reference Kim SG, Kim SN, Jong HS, Kim NK, Hong SH, Kim SJ, Bang YJ (2001) Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene 20:1254–1265CrossRefPubMed Kim SG, Kim SN, Jong HS, Kim NK, Hong SH, Kim SJ, Bang YJ (2001) Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene 20:1254–1265CrossRefPubMed
go back to reference Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ (2001) Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7:429–434PubMed Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ (2001) Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7:429–434PubMed
go back to reference Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625–631PubMed Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625–631PubMed
go back to reference Li M, Wu X, Xu XC (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7:1010–1016PubMed Li M, Wu X, Xu XC (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7:1010–1016PubMed
go back to reference Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase- 2 expression in the Barrett’s metaplasia-dysplasia- adenocarcinoma sequence. Am J Gastroenterol 96:990–996CrossRefPubMed Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase- 2 expression in the Barrett’s metaplasia-dysplasia- adenocarcinoma sequence. Am J Gastroenterol 96:990–996CrossRefPubMed
go back to reference Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S, Geisslinger G (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. Faseb J 15:1622–1624PubMed Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S, Geisslinger G (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. Faseb J 15:1622–1624PubMed
go back to reference Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ (2002) COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35:552–559CrossRefPubMed Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ (2002) COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35:552–559CrossRefPubMed
go back to reference Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG (2000) Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 28:514–521PubMed Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG (2000) Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 28:514–521PubMed
go back to reference Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857–860PubMed Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857–860PubMed
go back to reference Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C (2001) Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158:849–853PubMed Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C (2001) Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158:849–853PubMed
go back to reference Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS (2000) High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76:320–325CrossRefPubMed Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS (2000) High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76:320–325CrossRefPubMed
go back to reference Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up- regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86:2243–2249CrossRefPubMed Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up- regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86:2243–2249CrossRefPubMed
go back to reference Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146PubMed Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146PubMed
go back to reference Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM (2000) 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60:6846–6850PubMed Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM (2000) 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60:6846–6850PubMed
go back to reference Smalley WE, DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1–20PubMed Smalley WE, DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1–20PubMed
go back to reference Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ (2001) Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5’ CpG island in human gastric carcinoma cells. Cancer Res 61:4628–4635PubMed Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ (2001) Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5’ CpG island in human gastric carcinoma cells. Cancer Res 61:4628–4635PubMed
go back to reference Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94:585–591CrossRefPubMed Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94:585–591CrossRefPubMed
go back to reference Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637–2645CrossRefPubMed Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637–2645CrossRefPubMed
go back to reference Stark LA, Din FV, Zwacka RM, Dunlop MG (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. Faseb J 15:1273–1275PubMed Stark LA, Din FV, Zwacka RM, Dunlop MG (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. Faseb J 15:1273–1275PubMed
go back to reference Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMed Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMed
go back to reference Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMed Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMed
go back to reference Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 15:2057–2072CrossRefPubMed Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 15:2057–2072CrossRefPubMed
go back to reference Totzke G, Schulze-Osthoff K, Janicke, RU (2003) Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22: 8021-8030CrossRefPubMed Totzke G, Schulze-Osthoff K, Janicke, RU (2003) Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22: 8021-8030CrossRefPubMed
go back to reference Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23–28CrossRefPubMed Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23–28CrossRefPubMed
go back to reference Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120PubMed Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120PubMed
go back to reference Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331–367 Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331–367
go back to reference Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62:2029–2033 Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62:2029–2033
go back to reference Weppelmann B, Monkemeier D (1984) The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 17:196–199CrossRefPubMed Weppelmann B, Monkemeier D (1984) The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 17:196–199CrossRefPubMed
go back to reference Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908–7916CrossRefPubMed Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908–7916CrossRefPubMed
go back to reference Wolf BB, Schuler M, Echeverri F, Green DR (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 274:30651–30656CrossRefPubMed Wolf BB, Schuler M, Echeverri F, Green DR (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 274:30651–30656CrossRefPubMed
go back to reference Wong BC, Zhu GH, Lam SK (1999) Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 53:315–318CrossRefPubMed Wong BC, Zhu GH, Lam SK (1999) Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 53:315–318CrossRefPubMed
go back to reference Zheng TS, Flavell RA (2000) Divinations and surprises: genetic analysis of caspase function in mice. Exp Cell Res 256:67–73CrossRefPubMed Zheng TS, Flavell RA (2000) Divinations and surprises: genetic analysis of caspase function in mice. Exp Cell Res 256:67–73CrossRefPubMed
Metadata
Title
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target
Authors
Su-Hyeong Kim
Sang-Hyun Song
Sang-Gyun Kim
Kyung-Soo Chun
So-Young Lim
Hye-Kyung Na
Jae Weon Kim
Young-Joon Surh
Yung-Jue Bang
Yong-Sang Song
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0567-6

Other articles of this Issue 9/2004

Journal of Cancer Research and Clinical Oncology 9/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine